Vistagen Reports Positive Preliminary Data from PALISADE-3 Open-Label Extension for Fasedienol in Social Anxiety

summarizeSummary

Vistagen Therapeutics announced preliminary positive safety and exploratory efficacy data from the open-label extension of its PALISADE-3 Phase 3 study for fasedienol in social anxiety disorder, showing clinically relevant improvements and good tolerability.

check_boxKey Events

• Positive Preliminary Data

  Fasedienol showed clinically relevant improvements in social anxiety over four months in the open-label extension of the PALISADE-3 study, as measured by both clinician-administered (LSAS) and patient-reported (SPIN) scales.

• Good Tolerability Profile

  The fasedienol nasal spray was well-tolerated for up to 12 months in the open-label extension, with no new drug-related safety findings or serious adverse events identified.

• Follows Prior Phase 3 Failure

  This positive data from the open-label extension provides a new perspective after the randomized portion of PALISADE-3 failed to meet its primary endpoint in December 2025.

• Upcoming Clinical Milestones

  Topline data for the PALISADE-4 Phase 3 trial is expected in Q2 2026, and exploratory Phase 2 Repeat Dose Study data is anticipated in Q3 2026.

auto_awesomeAnalysis

This filing provides a much-needed positive update for Vistagen, especially after the randomized portion of the PALISADE-3 study failed its primary endpoint in December 2025. While the data is preliminary and from an open-label extension, it demonstrates clinically relevant improvements in both clinician-administered and patient-reported scales for social anxiety over several months, alongside a strong safety profile. This suggests fasedienol may be effective in real-world, as-needed use, a different context than the acute public speaking challenge where it previously fell short. For a company that recently disclosed substantial doubt about its ability to continue as a going concern, this positive clinical signal is critical for investor confidence and its ability to secure future financing. The market will now closely watch the upcoming PALISADE-4 topline data in Q2 2026.